AstraZeneca Annual Report and Form 20-F Information 2011

More documents

Recommendations

Info

Our core values sit at theheart of our culture: workingwith integrity and to highethical standards; showingrespect for the individual anddiversity; being open andhonest in all our interactions;and leading by example atall levels.We have a global R&D organisation and a track recordof creating medicines that meet some of the world’sgreatest disease challenges.> Our efforts are concentrated on unmet needs indisease areas where we believe our skills andexperience can make the most difference: cancer,cardiovascular, gastrointestinal disorders, infection,neurological disorders and respiratory conditions.85%A member of the Dow JonesSustainability Index since 2001, weachieved our highest ever assessmentscore in the 2011 World Index.> It can take more than 10 years and up to $1 billionto bring a new medicine to market. Many thousandsof compounds are investigated for their potential tobecome a new medicine. Only a few make itthrough the rigorous development process.> Our Responsible Business Plan provides the frameworkfor applying integrity and high ethical standards across allour activities.> Our commitment to the highest standards of sales andmarketing practice was underpinned in 2011 by our newGlobal External Interactions Policy which describes what isrequired to operate with the highest level of integrity in ourinteractions with public officials, healthcare professionals andcommunity organisations. Among other things, it places a banon providing gifts, other than low monetary value cultural itemsor educational items for the benefit of patients.> A Responsible Business Council comprising senior leadersand reporting to the Senior Executive Team has beenestablished. The Council will agree the Responsible Businessstrategy and oversee its implementation as measured bylong-term and annual objectives, targets and KPIs establishedby the relevant business functions and published in theResponsible Business Plan.For more information:> See the Responsible Business section which follows46 Health IntegrityAstraZeneca Annual Report and Form 20-F Information 2011
Delivering our strategyResponsible BusinessWe are committed to actingresponsibly and to the sustainabledevelopment of our businessOur continuing commitmentto enhancing the sustainabilityof our business wasdemonstrated by thelaunch of our ResponsibleBusiness Plan and thecreation of our ResponsibleBusiness Council”Dame Nancy RothwellNon-Executive Director, with responsibility foroverseeing Responsible BusinessIn this section we describe how we are workingto deliver business success responsibly,including summary information about ourcommitment and performance in certain keyareas. Further information about these areasand others is available on our website,astrazeneca.com/responsibility.IntroductionAt AstraZeneca, we are dedicated to the research, development,manufacture and marketing of medicines that make a difference inhealthcare. For us, this is at the core of our responsibility to ourstakeholders and to society. Successful pharmaceutical innovation,delivered responsibly, brings benefits for patients, creates sustainablevalue for shareholders and contributes to the economic developmentof the communities we serve.Previous sections have described our strategic business prioritiesand how we are enhancing our R&D, expanding our footprint inEmerging Markets, continuing our efforts to source innovation fromoutside AstraZeneca and increasingly working in partnerships thatbroaden the base for success in improving healthcare. At the sametime, we continue to drive efficiency and effectiveness across theorganisation, including increased outsourcing to a diverse range ofstrategic suppliers.All of these efforts are underpinned by our continued commitmentto the sustainable development of our business which delivers valuefor our stakeholders and for us. To that end, our responsible businessobjectives must be closely aligned to, and support delivery of, ourbusiness strategy. Our new Responsible Business Plan, published inApril 2011, provides our framework for delivering business successresponsibly. It puts at the top of our agenda those areas mostimpacted by our strategic priorities and which are therefore keyenablers of our business strategy.This means a specific focus on:> Clinical trials and animal research – underpinning our drive forinnovation with sound ethical R&D practice worldwide> Sales and marketing practices – driving consistently high ethicalstandards to promote our medicines responsibly worldwide> Access to healthcare – exploring ways of increasing access tohealthcare for underserved patient populations in a sustainable way> Human rights – making sure that we continue to develop and drivea consistent approach across all our activities> Diversity and inclusion – ensuring that diversity, in its broadestsense, is appropriately represented in our leadership, ourworkforce and our thinking. See the People section from page 40for more information> Suppliers – working only with organisations who embrace ethicalstandards that are consistent with our own.Business ReviewAstraZeneca Annual Report and Form 20-F Information 2011Delivering our strategy Responsible Business 47
Page 1 and 2: healthAstraZeneca Annual Reportand
Page 3 and 4: Financial summary$33.6bnSales down
Page 5 and 6: China: We announcedour decision to
Page 7 and 8: OverviewOperational overview7979 pr
Page 9 and 10: Chairman’s StatementI would like
Page 11 and 12: Chief Executive Officer’s ReviewA
Page 13 and 14: The process of getting a drug to ma
Page 15 and 16: OverviewnovationInnovation drives p
Page 17 and 18: Our Strategy and PerformanceMore pe
Page 19 and 20: Using the full range of innovative
Page 21 and 22: Our strategyMissionto make the most
Page 23 and 24: Our strategic priorities to 2014Our
Page 25 and 26: Our performance in 2011Our performa
Page 27 and 28: Business shapePeopleResponsible bus
Page 29 and 30: Strategy and PerformanceaborationIm
Page 31 and 32: Delivering our strategyOur strategy
Page 33 and 34: Development projects20112010 129342
Page 35 and 36: Investing in capabilitiesA core com
Page 37 and 38: Patent expiries for our key markete
Page 39 and 40: our Established Markets footprint i
Page 41 and 42: Product qualityWe are committed to
Page 43 and 44: We have a global approach, supporte
Page 45 and 46: ComplianceWe ensure a culture of et
Page 47: tegrityBusiness ReviewWe are dedica
Page 51 and 52: India has the fastest growing numbe
Page 53 and 54: ProtestsAstraZeneca acknowledges th
Page 55 and 56: Also in 2011, the DIHR in collabora
Page 57 and 58: healthcollaborationRaising breast c
Page 59 and 60: Pipeline by Therapy Area at 31 Dece
Page 62 and 63: Therapy Area ReviewIn September, we
Page 64 and 65: Therapy Area ReviewGastrointestinal
Page 66 and 67: Therapy Area ReviewInfectionTherapy
Page 68 and 69: Therapy Area ReviewIn the pipelineI
Page 70 and 71: Therapy Area ReviewOur financial pe
Page 72 and 73: Therapy Area ReviewOncologyTherapy
Page 74 and 75: Therapy Area Reviewendpoints of pro
Page 76 and 77: Therapy Area ReviewOur financial pe
Page 78 and 79: healthinnovationReducing the number
Page 80 and 81: Geographical ReviewUSAstraZeneca is
Page 82 and 83: Geographical ReviewEmerging Markets
Page 84 and 85: Disciplined execution of our strate
Page 86 and 87: Financial ReviewMeasuring performan
Page 88 and 89: Financial ReviewResults of operatio
Page 90 and 91: Financial ReviewFinancial position
Page 92 and 93: Financial ReviewCapitalisation and
Page 94 and 95: Financial ReviewResults of operatio
Page 96 and 97: Financial ReviewSensitivity analysi
Page 98 and 99:
Financial Reviewover the performanc
Page 100 and 101:
healthcollaborationFighting the ris
Page 102 and 103:
Board of Directors and Senior Execu
Page 104 and 105:
Board of Directors and Senior Execu
Page 106 and 107:
Corporate Governance ReportOperatio
Page 108 and 109:
Corporate Governance ReportThe Boar
Page 110 and 111:
Corporate Governance ReportDuring 2
Page 112 and 113:
Corporate Governance ReportBusiness
Page 114 and 115:
Corporate Governance ReportPolitica
Page 116 and 117:
Directors’ Remuneration ReportDav
Page 118 and 119:
Directors’ Remuneration ReportVar
Page 120 and 121:
Directors’ Remuneration ReportAdd
Page 122 and 123:
Directors’ Remuneration ReportSum
Page 124 and 125:
Directors’ Remuneration ReportSum
Page 126 and 127:
Directors’ Remuneration ReportIn
Page 128 and 129:
Directors’ Remuneration ReportPer
Page 130 and 131:
Directors’ Remuneration ReportGai
Page 132 and 133:
RiskManagement reporting and assura
Page 134 and 135:
RiskCommercialisation and business
Page 136 and 137:
RiskCommercialisation and business
Page 138 and 139:
RiskSupply chain and delivery risks
Page 140 and 141:
RiskEconomic and financial risks co
Page 142 and 143:
Financial StatementsPreparation of
Page 144 and 145:
Financial StatementsConsolidated St
Page 146 and 147:
Financial StatementsConsolidated St
Page 148 and 149:
Financial StatementsGroup Accountin
Page 150 and 151:
Financial StatementsProperty, plant
Page 152 and 153:
Financial StatementsNotes to the Gr
Page 154 and 155:
Financial Statements3 Finance incom
Page 156 and 157:
Financial Statements4 Taxation cont
Page 158 and 159:
Financial Statements6 Segment infor
Page 160 and 161:
Financial Statements9 Intangible as
Page 162 and 163:
Financial Statements10 Other invest
Page 164 and 165:
Financial Statements15 Financial in
Page 166 and 167:
Financial Statements15 Financial in
Page 168 and 169:
Financial Statements18 Post-retirem
Page 170 and 171:
Financial Statements18 Post-retirem
Page 172 and 173:
Financial Statements20 Share capita
Page 174 and 175:
Financial Statements23 Financial ri
Page 176 and 177:
Financial Statements23 Financial ri
Page 178 and 179:
Financial Statements24 Employee cos
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Financial Statements25 Commitments
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Financial Statements26 LeasesTotal
Page 194 and 195:
Financial StatementsIndependent Aud
Page 196 and 197:
Financial StatementsCompany Account
Page 198 and 199:
Financial Statements4 ReservesShare
Page 200 and 201:
Financial StatementsGroup Financial
Page 202 and 203:
Development PipelineNCEsPhase III/R
Page 204 and 205:
Development PipelineNCEsPhases I an
Page 206 and 207:
Shareholder Information> For shares
Page 208 and 209:
Shareholder InformationDocuments on
Page 210 and 211:
Corporate InformationHistory and de
Page 212 and 213:
GlossaryThe following abbreviations
Page 214 and 215:
Index2011 performance summary 23Acc
Page 216:
Contact informationRegistered offic
show all

AstraZeneca Annual Report and Form 20-F Information 2011

Create successful ePaper yourself

Delete template?

Save as template?